The present invention relates to novel compounds of formula ,to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases. In an embodiment, the modified red blood cell includes a target-binding agent. Signal outputs of the first set of are interconnected and signal outputs of the second set are separately interconnected to provide a signal output corresponding to each of thermal neutron flux and epithermal neutron flux entering the detector. The total power of the conversion device corresponds to an arc of the ring between the positions of a first slider and a second slider moveable around the ring, and the distribution of power between the converters is determined by the positions of the first and second sliders.